Study of TAK-672 in Participants With Acquired Hemophilia A

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 9, 2021

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions
Acquired Hemophilia A
Interventions
BIOLOGICAL

TAK-672

B-Domain Deleted Recombinant Porcine Factor VIII

Trial Locations (9)

Unknown

Gunma University Hospital, Maebashi

Nagoya University Hospital, Aichi

Nara Medical University Hospital, Kashihara-shi

Uonuma Kikan Hospital, Minamiuonuma

Jichi Medical University Hospital, Shimotsuke

Tokyo Saiseikai Central Hospital, Mita

Chiba University Hospital, Chiba

Fukushima Medical University Hospital, Fukushima

Yamagata University Hospital, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04580407 - Study of TAK-672 in Participants With Acquired Hemophilia A | Biotech Hunter | Biotech Hunter